[EN] AGONISTS OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR A7 SUBTYPE FOR USE IN THE TREATMENT OF COGNITIVE SYMPTOMS OF SCHIZOPHRENIA<br/>[FR] AGONISTES DU SOUS-TYPE A7 DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE NEURONAUX UTILISABLES DANS LE TRAITEMENT DE TROUBLES COGNITIFS DE LA SCHIZOPHRÉNIE
申请人:ABBVIE INC
公开号:WO2013177494A1
公开(公告)日:2013-11-28
The present invention relates to a pharmaceutical composition for use in the treatment of cognitive symptoms of schizophrenia comprising administering a therapeutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor a7 subtype and a pharmaceutically acceptable. The selective agonist of neuronal nicotinic acetylcholine receptor a7 subtype is preferably (4s)-4-(5- 3 7 phenyl-l,3,4-thiadiazol-2-yloxy)-l- azatricyclo[3.3.1.13,7 ]decane, N- [2-(pyridin-3-ylmethyl)-l-azabicyclo[2.2.2]oct-3-yl]-l- benzofuran-2- carboxamide, N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-chloro-l- benzothiophene-2-carboxamide, (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2- carboxamide or a salt thereof.